Jenburkt Pharmaceuticals shareholders approved all resolutions at its 41st Annual General Meeting on September 4, 2026, with near-unanimous support. The vote included the re-appointment of Dilip H. Bhuta as CFO for five years.

The company declared a dividend of ₹20.70 per share (207%) for FY26. Voting results were submitted to the BSE under Regulation 44(3) of the SEBI LODR Regulations, 2015. M/s. Nilesh Shah & Associates served as the scrutinizer.

Voting Results

A total of 7,332 shareholders were on record. While no shareholders attended physically, 51 participants joined via Video Conferencing. The promoter group held 2,057,450 shares and cast 1,916,350 votes in favor across key resolutions, representing 93.14% participation from their holdings.

Public non-institutional shareholders held 23,54,217 shares but polled only 9,795 votes (0.42%). Institutional public shareholders did not vote. Two votes were cast against the financial statements and dividend resolutions.

Governance and Compliance

The statutory and secretarial auditor reports contained no adverse qualifications. Independent Director Krishnan Subharaman was absent due to travel. The Chairman addressed 46 shareholder questions regarding financial results, product innovations, and market presence.

Leadership Continuity

Dilip H. Bhuta, aged 74, continues as Whole Time Director and CFO until March 31, 2032. He has served the company since July 2013. Remuneration is approved for the initial three-year period ending March 31, 2030. Bhuta brings 42 years of banking experience, having retired as Managing Director of BOB Cards Ltd in January 2012.

What the Numbers Show

The 207% dividend yield underscores strong cash generation relative to share capital. Combined with a debt-free balance sheet, this indicates a capital allocation strategy focused on returning value to shareholders rather than aggressive reinvestment.

Jenburkt Pharmaceuticals has promoted Prem Ashish Bhuta to the position of Associate Vice President (AVP) – Strategic Initiatives. The elevation, approved by the Board of Directors via circulation on September 4, 2026, takes effect immediately.

Bhuta, who joined the company on July 13, 2021, moves up from his previous role as Management Associate. The appointment follows recommendations from the Nomination and Remuneration Committee and received prior approval from the Audit Committee. This move aligns with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Profile and Experience

Bhuta, aged 26, holds a Master of Science in Integrated Marketing from New York University and a Bachelor of Commerce (Honours) from Narsee Monjee Institute of Management Studies, Mumbai. He brings over five years of cross-functional experience across finance, sales, marketing operations, and business analytics within the pharmaceutical sector.

During his tenure at Jenburkt, Bhuta progressed through roles including Management Trainee and Officer – Finance. His responsibilities have spanned new product development, e-commerce, sales tracking, inventory management, and exposure to manufacturing processes.

Strategic Contributions

Bhuta was part of the core team that built ZIXA Strong, an OTC topical pain relief brand under the company’s wellness division. He also contributed to broader technology modernization efforts, including:

• Deployment of artwork management software
• Upgrade of the Laboratory Information Management System (LIMS)
• Rollout of a real-time sales tracking application used by a field force of over 700 employees

Prior to joining Jenburkt, Bhuta undertook strategic research projects with organizations such as Samsung Electronics America and Coca-Cola Southwest Beverages during his academic tenure in the United States.

Related Party Disclosure

The filing discloses that Bhuta is related to Ashish U. Bhuta, the Promoter and Chairman & Managing Director of Jenburkt Pharmaceuticals. The details of the appointment were filed with BSE Ltd. under Ref. No.: JPL/CS/2342/2026.